Abstract
Schizophrenia is a devastating, chronic brain disorder afflicting about 1% percent of the population. The etiology, neuropathology, and pathophysiology of schizophrenia remain elusive. Intense research has been conducted in order to identify specific biological markers of schizophrenia. The gas nitric oxide (NO) is an important signaling molecule involved in many cellular events that take place in the cardiovascular, immune and nervous systems of animals. This present review aims to show that NO and its metabolites play eminent roles in schizophrenia and have a significant influence on our understanding of the development, progression and, possibly, treatment of the disease. Special emphasis is given to aspects of genetic linkage between NO generating and modulating proteins and schizophrenia, and the impact of NO metabolism on processes known to be disturbed in this neuropsychiatric disorder (i. e., nerve cell migration, formation and maintenance of synapses, N-methyl-D-aspartic acid receptor mediated neurotransmission, adult hippocampal neurogenesis, membrane pathology and cognitive abilities). Although certain alterations of brain NO metabolism are not unique to, or indicative of, schizophrenia, their modulation might be a promising therapeutic option for the future.
Keywords: Schizophrenia, Nitric oxide, Nitric oxide synthase(s), Brain, Genetics, Immunohistochemistry, Biochemistry, Cerebrospinal fluid, Blood, Animal models, Therapy, eNOS, iNOs, nNOS, CAPON
CNS & Neurological Disorders - Drug Targets
Title: Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy
Volume: 10 Issue: 7
Author(s): Hans-Gert Bernstein, Gerburg Keilhoff, Johann Steiner, Henrik Dobrowolny and Bernhard Bogerts
Affiliation:
Keywords: Schizophrenia, Nitric oxide, Nitric oxide synthase(s), Brain, Genetics, Immunohistochemistry, Biochemistry, Cerebrospinal fluid, Blood, Animal models, Therapy, eNOS, iNOs, nNOS, CAPON
Abstract: Schizophrenia is a devastating, chronic brain disorder afflicting about 1% percent of the population. The etiology, neuropathology, and pathophysiology of schizophrenia remain elusive. Intense research has been conducted in order to identify specific biological markers of schizophrenia. The gas nitric oxide (NO) is an important signaling molecule involved in many cellular events that take place in the cardiovascular, immune and nervous systems of animals. This present review aims to show that NO and its metabolites play eminent roles in schizophrenia and have a significant influence on our understanding of the development, progression and, possibly, treatment of the disease. Special emphasis is given to aspects of genetic linkage between NO generating and modulating proteins and schizophrenia, and the impact of NO metabolism on processes known to be disturbed in this neuropsychiatric disorder (i. e., nerve cell migration, formation and maintenance of synapses, N-methyl-D-aspartic acid receptor mediated neurotransmission, adult hippocampal neurogenesis, membrane pathology and cognitive abilities). Although certain alterations of brain NO metabolism are not unique to, or indicative of, schizophrenia, their modulation might be a promising therapeutic option for the future.
Export Options
About this article
Cite this article as:
Bernstein Hans-Gert, Keilhoff Gerburg, Steiner Johann, Dobrowolny Henrik and Bogerts Bernhard, Nitric Oxide and Schizophrenia: Present Knowledge and Emerging Concepts of Therapy, CNS & Neurological Disorders - Drug Targets 2011; 10 (7) . https://dx.doi.org/10.2174/187152711798072392
DOI https://dx.doi.org/10.2174/187152711798072392 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Stem Cells in Regenerative Medicine for Parkinson’s and Huntington’s Diseases
Current Medicinal Chemistry Quantifying Risk: The Role of Absolute and Relative Measures in Interpreting Risk of Adverse Reactions from Product Labels of Antipsychotic Medications
Current Drug Safety Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry Genetic Anomalies of the Respiratory Tract
Current Respiratory Medicine Reviews The Applications of Pharmacogenomics to Neurological Disorders
Current Molecular Medicine Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinsons disease
Current Pharmaceutical Design Mitochondrial Dysfunction in Huntington’s Disease: Pathogenesis and Therapeutic Opportunities
Current Drug Targets Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Current Neuropharmacology An Overview of Pharmacogenetics in Psychotropic Drugs
Current Psychiatry Reviews New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design Colchicine Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Surgical Ventricular Restoration: An Operation to Reverse Remodeling - Clinical Application (Part II) (Supplementry Table)
Current Cardiology Reviews Role of Dopamine Signaling in Drug Addiction
Current Topics in Medicinal Chemistry Phenytoin Induced Chorea: A Rare Adverse Effect of the Drug
Current Drug Safety Half a Century of l-DOPA
Current Topics in Medicinal Chemistry Causes of Secretion Retention: Patient Factors, Ventilation, Devices, Drugs
Current Respiratory Medicine Reviews 3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol: the Importance of Functional Groups for Antiparkinsonian Activity
Medicinal Chemistry Cannabinoids for the Treatment of Schizophrenia: An Overview
Current Topics in Medicinal Chemistry EDITORIAL (Thematic Issue: New Targets of Medical Treatment in Psychiatric Disorders)
Current Neuropharmacology